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Editorial
Insufficient implementation of the
IAP/APA guidelines on aetiology
in acute pancreatitis: Is there a
need for implementation managers
in pancreatology?
Identifying the aetiology of acute pancreatitis (AP) on
admission is crucially important in selecting the best and,
in some cases, the most specific therapy. For example,
early endoscopic retrograde cholangiopancreatography
is the best intervention in biliary AP with cholangitis,
lipid-lowering therapy in hypertriglyceridaemia-induced
AP, pancreatic stent placement in pancreatic duct
obstruction-evoked AP or steroid therapy in autoim-
mune pancreatitis. Unfortunately, the cause of AP
remains unclear in almost a quarter of all cases, a situ-
ation which could be due to either an insufficient diag-
nostic work-up or other unknown aetiological factors.
In addition, the importance of clear information on aeti-
ology is underlined by the fact that the cause of about
40% of fatal AP cases is idiopathic.1,2 It should also be
emphasised that knowing the aetiology is not only cru-
cial for the index AP, but also essential in preventing
recurrent or chronic pancreatitis.3,4 Therefore, it is not
surprising that the current IAP/APA guidelines suggest
endoscopic ultrasound (EUS) or magnetic resonance
cholangiopancreatography (MRCP) after a negative
work-up for biliary AP.5 Moreover, a genetic test is rec-
ommended after a second episode of idiopathic
pancreatitis in order to diagnose hereditary pancreatitis
or to understand the genetic risks of AP.5
In this current issue of the United European
Gastroenterology Journal, Hallensleben et al. investi-
gate the diagnostic work-up and outcomes of ‘pre-
sumed’ idiopathic AP after the first attack of AP.
Out of 191 first episodes of idiopathic AP patients,
176 underwent additional diagnosis, and the aetiolog-
ical factor was identified in 64/176 (36%) patients.
The underlying cause was mostly an occult biliary
stone or neoplasm, which established an aetiological
diagnosis, leading to a lower recurrence rate in these
patients (15% vs. 43%). They concluded that addi-
tional diagnostic evaluations and stronger adherence
to the current guidelines could identify the aetiology
in one third of cases.6 The study was conducted bril-
liantly. However, the article did not share information
on the level of diagnostic awareness (i.e. how many
idiopathic cases were due to an insufficient on-
admission diagnostic work-up) or adherence to the
last part of recommendation A3 of the guidelines,
which advises genetic testing after the second episode
of idiopathic AP.
Table 1. Distribution of aetiology of AP according to our AP registry with 2400 cases.
Aetiology
First AP
(N¼ 1791)
Second AP
(N¼ 325)
Third or more
AP (N¼ 284)
Idiopathic 358 (20%) 76 (24%) 70 (24%)
Biliary 835 (47%) 82 (25%) 20 (7%)
Alcohol induced 261 (15%) 84 (26%) 106 (37%)
Hypertriglyceridaemia,
hyperlipidaemia induced
65 (4%) 21 (6%) 21 (7%)
Alcoholþ hypertriglyceridaemia 47 (3%) 15 (5%) 6 (2%)
Combined 78 (4%) 10 (3%) 18 (6%)
Post ERCP 54 (3%) 6 (2%) 0
Other 93 (5%) 31 (10%) 43 (15%)
Values shown are n (%).
AP: acute pancreatitis; ERCP: endoscopic retrograde cholangiopancreatography.
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Therefore, in this brief, but very important study, we
analysed the international, multicentre, prospective AP
registry operated by the Hungarian Pancreatic Study
Group to answer the remaining two questions. We
investigated 2400 cases of AP uploaded from 30 centres
in 13 countries between 2012 and 2019. Of these, 1791
patients had a single AP attack, 325 had two and 284
had three or more (Table 1). Investigation of the first
episode of AP showed that biliary, alcoholic and
hypertriglyceridaemia-induced AP represent the three
most common aetiological factors responsible for the
inflammation. However, 20% of cases remained idio-
pathic, which is quite similar to the data published by
Hallensleben et al.6 (Table 1). Surprisingly, our results
showed that 5% of the patients left the hospital after
the first and second attacks of AP without any imaging
at all (Table 2). As regards the laboratory parameters,
25% of patients had no diagnostic work-up for biliary
AP (Table 3). Furthermore, the greatest insufficiency in
aetiology screening concerned lipid-induced (triglycer-
ide or cholesterol) pancreatitis: these measurements
were lacking in 71–76% of cases (Table 3).
In the second part of our study, we investigated the
additional diagnostic work-up for all idiopathic AP
after index admission. There was no search for biliary,
anatomic or cancer aetiology by EUS or MRCP in
91% of the cases, for autoimmune AP in 98% of
them, for genetic AP in 99% or for virus-induced AP
after the first attack in 94% (Table 4). A similar but
slightly better pattern was observed investigating the
second AP. However, we cannot be sure whether the
diagnostic work-up in these patients was not completed
during or after the first attack (Table 4).
We have previously shown that the implementation
of the IAP/APA guidelines is marked by major insuf-
ficiencies. Data from 9728 patients collected from 22
countries showed that Section F17 of the guidelines on
the prevention of infectious complications is rarely
used. In many countries, around 50% of patients
receive antibiotics incorrectly.7,8 Section L36 of the
guidelines recommends index admission cholecystecto-
my, which is still not applied in most hospitals.9
All in all, it is extremely depressing that scientists
spend a great deal of money on research and guidelines,
but they do not appear in everyday practice. Based on
these unpleasant data, it would appear to be high time
to create a new post, that of implementation manager,
responsible for strict adherence to management guide-
lines in order to ensure cost effectiveness and high qual-
ity in patient care.
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Table 2. Imaging during hospital stay.
First idiopathic
AP (N¼ 358)
Second idiopathic
AP (N¼ 76)
CT scan 126 (35%) 22 (29%)
Ultrasound 250 (70%) 55 (72%)
MRI 1 (0%) 2 (3%)
No imaging 17 (5%) 4 (5%)
Values shown are n (%).
CT: computed tomography; MRI: magnetic resonance imaging.
Table 3. Laboratory measurements during hospital stay.
First idiopathic
AP (N¼ 358)
Second idiopathic
AP (N¼ 76)
Chol 85 (24%) 18 (24%)
TG 101 (28% 22 (29%)
se-bi 268 (75%) 62 (82%)
GOT 242 (68%) 52 (68%)
GPT 231 (65%) 50 (66%)
ALP 291 (81%) 60 (79%
gGT 297 (83%) 59 (78%)
Values shown are n (%).
Chol: cholesterol; TG: triglyceride; se-bi: serum bilirubin level; GOT:
glutamic oxaloacetic transaminase; GPT: glutamic pyruvic transami-
nase; ALP: alkaline phosphatase; gGT: gamma-glutamyl transferase.
Table 4. Additional diagnostic work-up to identify the aeti-
ology after the first and the second episode of idiopathic AP.
First idiopathic
AP (N¼ 358)
Second idiopathic
AP (N¼ 76)
CT scan 24 (7%) 3 (4%)
EUS 18 (5%) 11 (14%)
MRCP 16 (4%) 9 (12%)
IgG4 6 (2%) 5 (7%)
Viral serology 20 (6%) 4 (5%)
Genetic testing 5 (1%) 9 (12%)
Values shown are n (%).
EUS: endoscopic ultrasound; MRCP: magnetic resonance
cholangiopancreatography.
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